CA125 Levels in Ovarian Cancer Patients
Author Information
Author(s): R.E. Hawkins, K. Roberts, E. Wiltshaw, J. Mundy, V.R. McCready
Primary Institution: Royal Marsden Hospital
Hypothesis
How effective is CA125 in predicting treatment responses and relapses in ovarian cancer patients?
Conclusion
CA125 is a sensitive and specific marker for monitoring treatment responses in ovarian cancer patients.
Supporting Evidence
- CA125 levels were shown to correlate with clinical status in ovarian cancer patients.
- The sensitivity and specificity for predicting response in patients with macroscopic disease were 95% and 86%, respectively.
- CA125 was useful in detecting relapse in patients with no known disease, with sensitivity and specificity of 86% and 91%, respectively.
- Residual disease was identified as the most important correlate of CA125 levels.
Takeaway
Doctors can use a blood test called CA125 to see how well treatment is working for women with ovarian cancer.
Methodology
CA125 levels were measured in patients with ovarian cancer during routine outpatient visits, and correlations with clinical status were analyzed.
Limitations
The study did not assess CA125 levels in real-time for treatment decisions, and some patients had low CA125 levels that complicated assessments.
Participant Demographics
Patients with epithelial ovarian carcinoma, including various histological types and stages.
Statistical Information
P-Value
<0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website